An announcement from Phathom Pharmaceuticals ( (PHAT) ) is now available.
Phathom Pharmaceuticals announced a leadership transition effective April 1, 2025, with Steven Basta appointed as the new Chief Executive Officer, President, and Class I director, succeeding Terrie Curran who resigned for personal reasons. The company also adopted a 2025 Employment Inducement Incentive Award Plan to attract new talent, reserving 2,500,000 shares for equity awards. This strategic move aims to strengthen the company’s leadership and incentivize new hires, potentially impacting its market position and stakeholder interests.
More about Phathom Pharmaceuticals
YTD Price Performance: -14.46%
Average Trading Volume: 1,130,160
Technical Sentiment Signal: Buy
Current Market Cap: $459.6M
See more data about PHAT stock on TipRanks’ Stock Analysis page.